taccalonolide AF

Taccalonolide AF is a highly potent microtubule-stabilizing agent, part of the taccalonolide class of compounds isolated from plants of the genus Tacca[2][7]. It acts by covalently binding to β-tubulin and irreversibly stabilizing microtubules, disrupting both interphase and mitotic microtubule dynamics[1][2][3][4]. This unique covalent mechanism distinguishes it from taxanes and other microtubule stabilizers, granting it the ability to overcome multiple clinically relevant mechanisms of drug resistance in cancer, including resistance mediated by drug efflux pumps and mutations in the taxane-binding site[1][2][4][5]. Taccalonolide AF exhibits potent antitumor efficacy in preclinical breast cancer models but is limited by a narrow therapeutic window and potential toxicity at higher doses[1][2][4]. Its mechanism of action is characterized by induction of persistent mitotic arrest, aberrant spindle morphologies, and inhibition of microtubule shortening and catastrophe[1]. Primary research and development have focused on its antineoplastic use, especially for drug-resistant cancers[2][4].